Fujian Cosunter Pharmaceutical, founded in June 2001, is a leading national high-tech enterprise focused on the treatment of liver diseases, antiviral and anti-infection drugs. They are known for their expertise in producing five major clinical medications for treating hepatitis B. Committed to transitioning from a traditional generic drug company to an innovative pharmaceutical enterprise, Fujian Cosunter Pharmaceutical continuously introduces and develops innovative and high-end generic drugs.

Their product portfolio includes a range of best-selling drugs in the fields of liver diseases, urology, cardiovascular, and traditional Chinese medicine. Recognized as a national enterprise technology center and a demonstration enterprise for intellectual property advantages in China, Fujian Cosunter Pharmaceutical successfully went public on the Shenzhen Stock Exchange on April 22, 2015 (stock code: 300436). With a dedication to scientific research and development, they strive to provide effective and reliable pharmaceutical solutions to improve the quality of patients' lives